Dehydroevodiamine Targeting ACHE and ALDH3A1 Regulate Glycolytic Metabolism to Inhibit Hepatocellular Carcinoma Cell Apoptosis

Dehydroevodiamine (DHE), a natural quinazoline alkaloid used in Chinese herbal medicine, exhibits promising antitumor properties various cancers, including gastric cancer. Glycolysis is essential for tumor proliferation and survival. The effect of DHE on hepatoma cells (hepatocellular carcinoma, HCC) the mechanism underlying glycolytic regulation remain unclear. In this study, cell viability, apoptosis rate, lactate release, glucose uptake were evaluated treated with DHE. Cell metabolites analyzed using GC-MS, network pharmacology was employed to identify potential drug targets Furthermore, antiproliferative liver cancer examined by silencing identified target. promotes Huh-7 PLC cells. metabonomics studies have shown that primarily modulates glycolysis/gluconeogenesis pathway. Simultaneously, can inhibit key enzymes HK2, PFKFB3, LDHA glycolysis pathway, thus inhibiting lactic acid production. Network pharmacological analysis ACHE ALDH3A1 as Silencing resulted loss apoptosis-promoting Thus, sensitizes aerobic directly downregulating ALDH3A1, leading inactivation suppression glycolysis. effectively inhibits progression cancer, reducing metabolism, thereby Therefore, could be agent molecular-targeted treatment strategies.